CT Screening For Lung Cancer in High Risk Patients: the Russian Study.
NCT ID: NCT01752647
Last Updated: 2019-09-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
369 participants
INTERVENTIONAL
2012-11-30
2016-09-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
CT Scans in Screening for Lung Cancer in Current and Former Smokers
NCT00625690
Early Lung Cancer Detection Using Computed Tomography
NCT00188734
Continuous Observation of Smoking Subject
NCT01248806
Evaluation of Lung Cancer CT Screening Performance Among Former and Current Smokers
NCT05486455
Early Detection of Lung Cancer in Czech High-risk Asymptomatic Individuals
NCT04627350
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The purpose of this study is to assess the feasibility of establishing a lung cancer screening program in Russian Federation using LDCT scanning in asymptomatic patients with at least a 30 pack-year history of cigarette smoking. This cohort prospective study is planned to enroll at least 500 current or former smokers.
Patients will be screened by LDCT scan at baseline with recommendation to perform follow-up in case of any positive result. For nodes more than 10 mm full clinical examination is recommended. For nodes 3-9.9 mm follow-up scans in 1, 3 or 6 months is recommended. For nodes smaller than 3 mm and negative results annual LDCT is recommended. Patient with positive results will be followed until final clinical diagnosis.
Secondary outcomes include:
* Lung cancer diagnoses
* Lung cancer and overall mortality
* Quality of life assessment
* Complications of diagnostic and surgical procedures following a positive result.
* Comparison of independent radiological evaluation of scans.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SCREENING
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Low dose computed tomography
Patients will have one baseline LDCT scan.
Low dose computed tomography
Low dose computed tomography scan
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Low dose computed tomography
Low dose computed tomography scan
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* 30 or more pack-years of cigarette smoking history
* Former smokers: quit smoking within the previous 10 years
* Ability to tolerate CT procedure
* Signed informed consent
Exclusion Criteria
* Severe uncontrolled heart, vascular, respiratory or endocrine pathology.
* Life-expectancy less than 1 year
* History of lung cancer
* History of lung surgery.
* Acute respiratory disease
* Hemoptysis.
* Weight loss more than 10 kg in the 12 months prior to eligibility assessment
* Participation in other cancer clinical trial
* Chest CT examination in the 12 months prior to eligibility assessment.
50 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
N.N. Petrov National Medical Research Center of Oncology
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alexei Barchuk, MD PhD
Role: STUDY_CHAIR
N.N. Petrov National Medical Research Center of Oncology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Semashko City Clinical Hospital #2
Samara, Samara Oblast, Russia
Samara Regional Oncology Dispansery
Samara, Samara Oblast, Russia
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
RLCT-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.